The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial
Open Access
- 13 December 2014
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 15 (1) , 489
Abstract
Adequate monitoring tools are required to optimise the immunosuppressive therapy of an individual patient. Particularly, in calcineurin inhibitors, as critical dose drugs with a narrow therapeutic range, the optimal monitoring strategies are discussed in terms of safety and efficacy. Nevertheless, no pharmacokinetic monitoring markers reflect the biological activity of the drug. A new quantitative analysis of gene expression was employed to directly measure the functional effects of calcineurin inhibition: the transcriptional activities of the nuclear factor of activated T-cell (NFAT)-regulated genes in the peripheral blood.Keywords
This publication has 40 references indexed in Scilit:
- Pharmacodynamic Monitoring of Cyclosporin A Reveals Risk of Opportunistic Infections and Malignancies in Renal Transplant Recipients 65 Years and OlderTherapeutic Drug Monitoring, 2011
- Aortic Stiffness and Central Wave Reflections Predict Outcome in Renal Transplant RecipientsHypertension, 2011
- Pharmacokinetic and pharmacodynamic analysis of enteric‐coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patientsBritish Journal of Clinical Pharmacology, 2010
- Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant PatientsClinical Journal of the American Society of Nephrology, 2010
- New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ TransplantationTherapeutic Drug Monitoring, 2009
- Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled TrialTransplantation, 2008
- Ciclosporin A Tapering Monitored by NFAT-Regulated Gene Expression: A New Concept of Individual ImmunosuppressionTransplantation, 2008
- Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipientsTransplant International, 2007
- Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine ATransplantation, 2004
- Recognition of NFATp/AP-1 composite elements within genes induced upon the activation of immune cellsJournal of Molecular Biology, 1999